A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity
NCT07783854 on ClinicalTrials.gov · last registry update 2026-08-25
Registered but not yet open, with 72 participants planned. Due to report 30 December 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Percentage change in body weight from baseline to week 24. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Sponsor type
- Other
- Enrollment
- 72
- Started
- 2026-09-01
- Primary completion
- 2027-12-30 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-25 | First seen in registry | Registered as NOT_YET_RECRUITING, P4 |
Primary outcome
Percentage change in body weight from baseline to week 24
Conditions studied
Obesity & Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.